BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale. - 2From Exemplary to Current: Famous Rings Available
- 3College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- 4Moderna to complete US mRNA manufacturing network with $140 million investment
- 5In the background: Visiting Notable Film Areas All over the Planet
- New 'People We Meet on Vacation' trailer teases Poppy and Alex romance: Everything we know about the new Netflix movie
- Electric Vehicles for Eco-Accommodating Driving
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
- Iran war drives global fertilizer prices up, raising food cost fears
- 1,000-mile Saharan dust storm, from the sky and from the ground
- Fisherman Attacked by Great White Shark Says ‘My Left Foot Was in His Mouth’
- 5 Great Crossover Vehicles For Eco-friendliness In 2024
- AI’s errors may be impossible to eliminate – what that means for its use in health care
- How to watch the last supermoon of the year
